Aucta Pharmaceuticals, Inc.
🇺🇸United States
Clinical Trials
4
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
3
FDA:2
NMPA:1
Drug Approvals
Vigabatrin Powder for Oral Solution
- Product Name
- 氨己烯酸口服溶液用散
- Approval Number
- 国药准字HJ20210049
- Approval Date
- Jun 25, 2021
NMPA
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
Phase 2
Terminated
- Conditions
- Tuberous SclerosisAngiofibroma of Face
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Aucta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT03363763
- Locations
- 🇺🇸
Translational Genomics Research, Phoenix, Arizona, United States
🇺🇸Children's Hospital of Los Angeles, Division of Neurology, Los Angeles, California, United States
🇺🇸Children's Clinical Research Organization, Children's Hospital Colorado, Aurora, Colorado, United States
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Aucta Pharmaceuticals, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT03239353
- Locations
- 🇦🇺
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
News
No news found